Physician profile
Anthony Burke
NPI 1700906427
$6,202.44
in general payments reported to CMS, 2019-2025
27 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $535 · 2021: $1,041 · 2022: $1,258 · 2023: $1,174 · 2024: $534 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,170.32 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $725.80 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $629.82 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $519.15 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $501.68 | 2019-2024 | Andexxa, Farxiga |
| Merck Sharp & Dohme LLC | $442.81 | 2023-2025 | Verquvo |
| Pfizer INC. | $325.20 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $305.72 | 2021-2025 | |
| Boston Scientific Corporation | $300.36 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Watchman Access System |
| Daiichi Sankyo INC. | $247.53 | 2019-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.04 | 2021-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.33 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $142.24 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $112.19 | 2021-2023 | Reveal Linq |
| Inspire Medical Systems, INC. | $63.52 | 2025 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $57.13 | 2019-2020 | |
| Cardiovascular Systems INC. | $52.63 | 2019-2023 | Diamondback Peripheral |
| Abbott Laboratories | $49.60 | 2023 | Assurity, Diamondback Peripheral |
| Alexion Pharmaceuticals, INC. | $43.17 | 2022 | |
| Astellas Pharma US INC | $33.13 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $29.76 | 2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Actelion Pharmaceuticals US, INC. | $24.69 | 2019-2020 | |
| Medtronic Vascular, INC. | $23.32 | 2019 | |
| Gilead Sciences, INC. | $17.32 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.47 | 2019 | |
| Esperion Therapeutics, INC. | $15.28 | 2025 | Nexletol |
| Elutia, INC. | $15.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.